千金药业(600479) - 2020 Q1 - 季度财报

Financial Performance - Operating income decreased by 0.13% to CNY 803,008,185.83 year-on-year[5] - Net profit attributable to shareholders decreased by 16.19% to CNY 37,725,338.92 compared to the same period last year[5] - Basic earnings per share decreased by 16.26% to CNY 0.0901[5] - The company reported a net profit of CNY 36,311,513.87, down 11.61% year-on-year[5] - Net profit for Q1 2020 was ¥45,298,319.73, down 18.2% from ¥55,348,091.30 in Q1 2019[35] - The total profit for Q1 2020 was CNY 27,499,536.77, an increase of 5.1% from CNY 26,155,937.40 in Q1 2019[40] Cash Flow - Cash flow from operating activities increased by 107.75% to CNY 99,875,418.96 year-on-year[5] - Cash flow from operating activities generated a net amount of CNY 99,875,418.96, significantly higher than CNY 48,074,675.33 in Q1 2019, marking an increase of 107.4%[43] - Cash flow from investing activities decreased by 106.80% year-on-year, primarily because the company had no investment recovery during the period[22] - Cash flow from financing activities increased significantly, with a net cash inflow of 116.45 million yuan, mainly due to special loans obtained for epidemic prevention[23] - Cash flow from financing activities resulted in a net inflow of CNY 116,448,501.97 in Q1 2020, compared to a net outflow of CNY 2,738,117.98 in Q1 2019[44] Assets and Liabilities - Total assets increased by 3.65% to CNY 3,951,468,620.82 compared to the end of the previous year[5] - Total current assets amounted to ¥3,100,927,241.62, an increase from ¥2,955,282,230.64 as of December 31, 2019, representing a growth of approximately 4.9%[28] - Total liabilities increased to ¥1,276,588,596.87 from ¥1,182,596,267.88, which is an increase of about 7.9%[29] - Total liabilities rose to ¥603,040,358.15, compared to ¥459,832,914.40 in the previous year, marking an increase of 31.1%[33] - The company's total liabilities to equity ratio is approximately 27.1%, indicating a conservative leverage position[55] Shareholder Information - The total number of shareholders reached 42,325 at the end of the reporting period[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[10] Receivables and Prepayments - Accounts receivable increased by 51.07% compared to the end of last year, primarily due to the company's collection policy leading to an increase in accounts receivable[13] - Prepayments increased by 86.09% compared to the end of last year, mainly due to the company's increased prepayments for pandemic prevention materials[14] - Other receivables increased by 166.65% compared to the end of last year, primarily due to an increase in cash advances and guarantees paid by the company[15] Other Income and Expenses - Other income decreased by 66.59% year-on-year, mainly due to a reduction in government subsidies received during the period[18] - Investment income decreased by 100% year-on-year, as the company had no short-term investment income during the period[19] - The company reported a decrease in research and development expenses to ¥17,668,968.25, down 7.8% from ¥19,168,032.20 in the previous year[34] Equity and Retained Earnings - Total equity as of March 31, 2020, was ¥2,674,880,023.95, up from ¥2,629,576,479.61, indicating a growth of approximately 1.7%[30] - The company’s retained earnings were reported at $534,321,856.22, showcasing a strong accumulation of profits over time[55]